Streetbeat News

Revenues

QNRX

Quoin Pharmaceuticals reported having approximately $12.6 million in cash, cash equivalents, and marketable securities as of June 30, 2024. This funding is expected to support the company's operations into late 2025.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:33 pm

HBIO

Harvard Bioscience (NASDAQ:HBIO) reported Q2 2024 earnings of $0.00 per share, missing the analyst estimate of $0.05 by 98%. Sales were $23.097M, missing the $26.400M estimate by 12.51%. Both earnings and sales showed significant declines compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:33 pm

EDRY

EuroDry (NASDAQ:EDRY) reported Q2 2024 adjusted EPS of $(0.17), missing the analyst estimate of $0.52 by 132.69%. Sales were $17.437M, missing the $18.145M estimate by 3.90%. Despite the misses, EPS improved by 64.58% and sales increased by 68.60% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:31 pm

DXYN

Dixie Group (NASDAQ:DXYN) reported Q2 earnings of $0.04 per share, a significant improvement from a loss of $(0.12) per share YoY. However, sales decreased by 4.73% to $70.51 million from $74.01 million YoY.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:31 pm

UP

Wheels Up Experience (NYSE:UP) reported Q2 EPS of $(0.14), a significant improvement from $(6.28) YoY. However, sales dropped 41.42% YoY to $196.28M from $335.06M.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:30 pm

OGEN

Oragenics has announced that its product ONP-002 has a potential addressable market opportunity that includes an estimated 69 million concussions globally.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:30 pm

AURA

Aura Biosciences reported a Q2 2024 GAAP EPS of $(0.41), beating the estimate of $(0.46). The company has cash, cash equivalents, and marketable securities totaling $187.4 million, which are expected to fund operations into the second half of 2026.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:28 pm

LLY

Eli Lilly (NYSE: LLY) reported strong Q2 earnings, with revenue of $11.3 billion, up 36% YoY, surpassing estimates. The growth was driven by increased sales of diabetes and weight loss drugs, particularly Mounjaro, Zepbound, Verzenio, Taltz, and Jardiance. The company raised its 2024 sales and EPS guidance, reflecting confidence in continued strong performance.

Portfolio Pulse from Vandana Singh

August 08, 2024 | 12:26 pm

FHTX

Foghorn Therapeutics reported its Q2 2024 financial results, with a GAAP EPS of $(0.45) beating the estimate of $(0.47). Sales were $6.888M, surpassing the $6.094M estimate. The company has $285.2M in cash, cash equivalents, and short-term investments as of June 30, 2024, extending its expected cash runway into 2027.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:25 pm

PRQR

ProQR Therapeutics reported a Q1 2024 GAAP EPS of €(0.03), beating the estimate of €(0.11). However, sales of €6.305M missed the estimate of €11.460M. The company has a cash position of €96.2M as of the end of Q2, providing a runway into mid-2026.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:22 pm